Cargando…
Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailment...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873527/ https://www.ncbi.nlm.nih.gov/pubmed/29510918 http://dx.doi.org/10.1016/j.vaccine.2018.02.055 |
_version_ | 1783310046244896768 |
---|---|
author | Hussain, Imtiaz Mach, Ondrej Hamid, Nasir A. Bhatti, Zaid S. Moore, Deborah D. Oberste, M. Steven Khan, Shahid Khan, Hasan Weldon, William C. Sutter, Roland W. Bhutta, Zulfiqar A Soofi, Sajid B. |
author_facet | Hussain, Imtiaz Mach, Ondrej Hamid, Nasir A. Bhatti, Zaid S. Moore, Deborah D. Oberste, M. Steven Khan, Shahid Khan, Hasan Weldon, William C. Sutter, Roland W. Bhutta, Zulfiqar A Soofi, Sajid B. |
author_sort | Hussain, Imtiaz |
collection | PubMed |
description | BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we collected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies. RESULTS: A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to poliovirus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and 91% for PV2; 93% and 98% for PV3. Age group (RR = 3.6, CI 95% = 2.2–5.6) and place of residence outside of Kandahar city (RR = 1.8, CI 95% = 1.2–2.6) were found to be significant risk factors for seronegativity. CONCLUSIONS: The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication. |
format | Online Article Text |
id | pubmed-5873527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58735272018-04-05 Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 Hussain, Imtiaz Mach, Ondrej Hamid, Nasir A. Bhatti, Zaid S. Moore, Deborah D. Oberste, M. Steven Khan, Shahid Khan, Hasan Weldon, William C. Sutter, Roland W. Bhutta, Zulfiqar A Soofi, Sajid B. Vaccine Article BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we collected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies. RESULTS: A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to poliovirus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and 91% for PV2; 93% and 98% for PV3. Age group (RR = 3.6, CI 95% = 2.2–5.6) and place of residence outside of Kandahar city (RR = 1.8, CI 95% = 1.2–2.6) were found to be significant risk factors for seronegativity. CONCLUSIONS: The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication. Elsevier Science 2018-04-05 /pmc/articles/PMC5873527/ /pubmed/29510918 http://dx.doi.org/10.1016/j.vaccine.2018.02.055 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Hussain, Imtiaz Mach, Ondrej Hamid, Nasir A. Bhatti, Zaid S. Moore, Deborah D. Oberste, M. Steven Khan, Shahid Khan, Hasan Weldon, William C. Sutter, Roland W. Bhutta, Zulfiqar A Soofi, Sajid B. Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title_full | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title_fullStr | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title_full_unstemmed | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title_short | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 |
title_sort | seroprevalence of anti-polio antibodies in children from polio high risk area of afghanistan: a cross sectional survey 2017 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873527/ https://www.ncbi.nlm.nih.gov/pubmed/29510918 http://dx.doi.org/10.1016/j.vaccine.2018.02.055 |
work_keys_str_mv | AT hussainimtiaz seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT machondrej seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT hamidnasira seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT bhattizaids seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT mooredeborahd seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT oberstemsteven seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT khanshahid seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT khanhasan seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT weldonwilliamc seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT sutterrolandw seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT bhuttazulfiqara seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 AT soofisajidb seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017 |